Synthesis, antifungal activity of caffeic acid derivative esters, and their synergism with fluconazole and nystatin against Candida spp.

Diagnostic Microbiology and Infectious Disease

Volumn 86, Issue 4, 2016, Pages 387-391

  Sardi, Janaína de Cássia Orlandi ^a,b   Gullo, Fernanda Patrícia ^a   Freires, Irlan Almeida ^b   Pitangui, Nayla de Souza ^a   Segalla, Maicon Petrônio ^a   Fusco Almeida, Ana Marisa ^a   Rosalen, Pedro Luiz ^b   Regasini, Luís Octávio ^a,c   Mendes Giannini, Maria José Soares ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Department of Biology Institute of Biosciences Humanities and Exact Sciences   (Brazil)

Author keywords

Antifungal; Caffeic acid; Candida albicans; Synergism

Indexed keywords

BUTYL CAFFEATE; CAFFEIC ACID; CAFFEIC ACID DERIVATIVE; ETHYL CAFFEATE; FLUCONAZOLE; HEPTYL CAFFEATE; HEXYL CAFFEATE; METHYL CAFFEATE; NYSTATIN; OCTYL CAFFEATE; PENTYL CAFFEATE; PROPYL CAFFEATE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ESTER;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS ISOLATION; HUMAN; HUMAN CELL; IC50; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; CANDIDIASIS; CELL CULTURE; CHEMICAL STRUCTURE; DRUG EFFECTS; DRUG POTENTIATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; SYNTHESIS;

ANTIFUNGAL AGENTS; CAFFEIC ACIDS; CANDIDA ALBICANS; CANDIDIASIS; CELLS, CULTURED; DRUG SYNERGISM; ESTERS; FLUCONAZOLE; HUMANS; INHIBITORY CONCENTRATION 50; KERATINOCYTES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NYSTATIN;

EID: 84994234378     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.08.002     Document Type: Article

References (44)

1. Al Mubarak, S, Robert, AA, Baskaradoss, JK, Al-Zoman, K, Al Sohail, A, Alsuwyed, A, et al. The prevalence of oral Candida infections in periodontitis patients with type 2 diabetes mellitus. J Infect Public Health 6 (2013), 296–301.
2. Aprotosoaie, AC, Hăncianu, M, Poiată, A, Tuchiluş, C, Spac, A, Cioană, O, et al. In vitro antimicrobial activity and chemical composition of the essential oil of Foeniculum vulgare Mill. Rev Med Chir Soc Med Nat Iasi 112 (2008), 832–836.
3. Balachandran, C, Duraipandiyan, V, Al-Dhabi, NA, Balakrishna, K, Kalia, NP, Rajput, VS, et al. Antimicrobial and Antimycobacterial activities of methyl caffeate isolated from Solanum torvum Swartz. Fruit Indian J Microbiol 52 (2012), 676–681.
4. Bax, R, Green, S, Antibiotics: the changing regulatory and pharmaceutical industry paradigm. J Antimicrob Chemother 70 (2015), 1281–1284.
5. Clinical and Laboratory Standards Institute (CLSI), Protocol M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed., 2008, CLSI, Pennsylvania.
6. Dai, L, Zang, C, Tian, S, Liu, W, Tan, S, Cai, Z, et al. Design, synthesis, and evaluation of caffeic acid amides as synergists to sensitize fluconazole-resistant Candida albicans to fluconazole. Bioorg Med Chem Lett 25 (2015), 34–37.
7. Denning, DW, Gugnani, HC, Burden of serious fungal infections in Trinidad and Tobago. Mycoses 58 (2015), 80–84.
8. Epstein, JB, Dawson, JR, Buivids, IA, Wong, B, Le, ND, The effect of a disinfectant/coolant irrigant on microbes isolated from dental unit water lines. Spec Care Dentist 22 (2002), 137–141.
9. Fernández-Ruiz, M, Puig-Asensio, M, Guinea, J, Almirante, B, Padilla, B, Almela, M, et al. Candida tropicalis bloodstream infection: incidence, risk factors and outcome in a population-based surveillance. J Infect 71 (2015), 385–394.
10. Freires, IA, Queiroz, VC, Furletti, VF, Ikegaki, M, de Alencar, SM, Duarte, MC, et al. Chemical composition and antifungal potential of Brazilian propolis against Candida spp. J Mycol Med, 2016, 10.1016/j.mycmed.2016.01.003.
11. Freitas, EM, Monteiro, LC, Fernandes, MB, Martelli Junior, H, Bonan, PR, Nobre, SA, Antifungal susceptibility in vitro determined by the Etest® for Candida obtained from the oral cavity of irradiated and elderly individuals. Braz Dent J 26 (2015), 99–104.
12. Fu, J, Cheng, K, Zhang, Z, Fang, R, Zhu, H, Synthesis, structure and structure–activity relationship analysis of caffeic acid amides as potential antimicrobials. Eur J Med Chem 45 (2010), 2638–2643.
13. Gabler, IG, Barbosa, AC, Velela, RR, Lyon, S, Rosa, CA, Incidence and anatomic localization of oral candidiasis in patients with AIDS hospitalized in a public hospital in Belo Horizonte, MG, Brazil. J Appl Oral Sci 16 (2008), 247–250.
14. Garcia-Cuesta, C, Sarrion-Pérez, MG, Bagán, JV, Current treatment of oral candidiasis: a literature review. J Clin Exp Dent 6 (2014), e576–e582.
15. Gullo, FP, Sardi, JC, Santos, VA, Sangalli-Leite, F, Pitangui, NS, Rossi, SA, et al. Antifungal activity of maytenin and pristimerin. Evid Based Complement Alternat Med, 2012, 2012, 340787.
16. Han, Y, Lee, JH, Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol Pharm Bull 28 (2005), 541–544.
17. Han, B, Chen, J, Yu, Y, Cao, Y, Jiang, Y, Antifungal activity of Rubus chingii extract combined with fluconazole against fluconazole-resistant Candida albicans. Microbiol Immunol 60 (2016), 82–92.
18. Hannula, J, Dogan, B, Slots, J, Okte, E, Asikainen, S, Subgingival strains of Candida albicans in relation to geographical origin and occurrence of periodontal pathogenic bacteria. Oral Microbiol Immunol 16 (2001), 113–118.
19. Kuo, YY, Jim, WT, Su, LC, Chung, CJ, Lin, CY, Huo, C, et al. Caffeic acid phenethyl ester is a potential therapeutic agent for oral cancer. Int J Mol Sci 16 (2015), 10748–10766.
20. Liao, X, Qiu, H, Li, R, Guo, F, Liu, W, Kang, M, et al. Risk factors for fluconazole-resistant invasive candidiasis in intensive care unit patients: an analysis from the China survey of candidiasis study. J Crit Care 30 (2015), 862.e1–862.e5.
21. Manfredi, M, McCullough, MJ, Al-Karaawi, ZM, Vescovi, P, Porter, SR, In vitro evaluation of virulence attributes of Candida spp. isolated from patients affected by diabetes mellitus. Oral Microbiol Immunol 21 (2006), 183–189.
22. Mora-Navarro, C, Méndez-Vega, J, Caraballo-León, J, Lee, M-r, Palecek, S, Torres-Lugo, M, et al. Hydrophobicity of antifungal β-peptides is associated with their cytotoxic effect on in vitrohuman colon Caco-2 and liver HepG2 cells. PLoS One, 11(3), 2016, e0149271, 10.1371/journal. pone.0149271.
23. Newman, DJ, Cragg, GM, Natural products as sources of new drugs over the 30 Years from 1981 to 20140. J Nat Prod, 2016, 10.1021/acs.jnatprod.5b01055 [in press].
24. Nihei, K, Nihei, A, Kubo, I, Rational design of antimicrobial agents: antifungal activity of alk(en)yl dihydroxybenzoates and dihydroxyphenyl alkanoates. Bioorg Med Chem Lett 13 (2003), 3993–3996.
25. Paracatu, LC, Bonacorsi, C, de Farias, CM, Nazare, AC, Petronio, MS, Regasini, LO, et al. Alkyl caffeates as anti–Helicobacter pylori and scavenger of oxidants produced by neutrophils. Med Chem 10 (2014), 74–80.
26. Pippi, B, Lana, AJD, Moraes, RC, Güez, CM, Machado, M, Oliveira, LFS, et al. In vitro evaluation of the acquisition of resistance, antifungal activity and synergism of Brazilian red propolis with antifungal drugs on Candida spp. J Appl Microbiol 118 (2015), 839–850.
27. Reynaud, AH, Nygaard-Østby, B, Bøygard, GK, Eribe, ER, Olsen, I, Gjermo, P, Yeasts in periodontal pockets. J Clin Periodontol 28 (2001), 860–864.
28. Rodrigues, FF, Oliveira, LG, Rodrigues, FF, Saraiva, ME, Almeida, SC, Cabral, ME, et al. Chemical composition, antibacterial and antifungal activities of essential oil from Cordia verbenacea DC leaves. Pharmacognosy Res 4 (2012), 161–165.
29. Rodriguez-Tudela, JL, Alastruey-Izquierdo, A, Gago, S, Cuenca-Estrella, M, León, C, Miro, JM, et al. Burden of serious fungal infections in Spain. Clin Microbiol Infect 21 (2015), 183–189.
30. Rosato, A, Vitali, C, Piarulli, M, Mazzotta, M, Argentieri, MP, Mallamaci, R, In vitro synergic efficacy of the combination of nystatin with the essential oils of Origanum vulgare and Pelargonium graveolens against some Candida species. Phytomedicine 16 (2009), 972–975.
31. Rzepecka-Stojko, A, Kabała-Dzik, A, Moździerz, A, Kubina, R, Wojtyczka, RD, Stojko, R, et al. Caffeic acid phenethyl ester and ethanol extract of propolis induce the complementary cytotoxic effect on triple-negative breast cancer cell lines. Molecules 20 (2015), 9242–9262.
32. Sanguinetti, M, Posteraro, B, Lass-Flörl, C, Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses 58 (2015), 2–13.
33. Sardi, JC, Duque, C, Höfling, JF, Gonçalves, RB, Genetic and phenotypic evaluation of Candida albicans strains isolated from subgingival biofilm of diabetic patients with chronic periodontitis. Med Mycol 50 (2012), 467–475.
34. Scorzoni, L, Benaducci, T, Fusco-Almeida, AM, Silva, DHS, Bolzani, VS, Mendes-Giannini, MJS, The use of standard methodology for determination of antifungal activity of natural products against medical yeasts Candida sp and Cryptococcus sp. Braz J Microbiol 38 (2007), 391–397.
35. Seifi, Z, Zarei-Mahmoudabadi, A, Zarrin, M, Extracellular enzymes and susceptibility to fluconazole in Candida strains isolated from patients with vaginitis and healthy individuals. Jundishapur J Microbiol, 8, 2015, e20162.
36. Soares, LA, Gullo, FP, Sardi Jde, C, Pitangui Nde, S, Costa-Orlandi, CB, Sangalli-Leite, F, et al. Anti-trichophyton activity of protocatechuates and their synergism with fluconazole. Evid Based Complement Alternat Med, 2014, 2014, 957860.
37. Soll, DR, Candida commensalism and virulence: the evolution of phenotypic plasticity. Acta Trop 81 (2002), 101–110.
38. Stringaro, A, Vavala, E, Colone, M, Pepi, F, Mignogna, G, Garzoli, S, et al. Effects of Mentha suaveolensessential oil alone or in combination with other drugs in Candida albicans. Evid Based Complement Alternat Med, 2014, 2014, 125904.
39. Svetaz, LA, Postigo, A, Butassi, E, Zacchino, SA, Sortino, MA, Antifungal drugs combinations: a patent review 2000–2015. Exp Opin Therapeut Patent, 2016, 10.1517/13543776.2016.1146693 [in press].
40. Tekeli, A, Dolapci, I, Emral, R, Cesur, S, Candida carriage and Candida dubliniensis in oropharyngeal samples of type-1 diabetes mellitus patients. Mycoses 47 (2004), 315–318.
41. Thurnheer, T, Bostanci, N, Belibasakis, GN, Microbial dynamics during conversion from supragingival to subgingival biofilms in an in vitro model. Mol Oral Microbiol, 2015, 10.1111/omi.12108.
42. Touaibia, M, Jean-François, J, Doiron, J, Caffeic acid, aversatile pharmacophore: an overview. Mini-Rev Med Chem 11 (2011), 695–713.
43. Ying, Y, Zhao, Y, Hu, X, Cai, Z, Liu, X, Jin, G, et al. In vitro fluconazole susceptibility of 1,903 clinical isolates of Candida albicans and the identification of ERG11 mutations. Microb Drug Resist 19 (2013), 266–273.
44. Zomorodian, K, Kavoosi, F, Pishdad, GR, Mehriar, P, Ebrahimi, H, Bandegani, A, et al. Prevalence of oral Candida colonization in patients with diabetes mellitus. J Mycol Med, 2016, 10.1016/j.mycmed.2015.12.008.